Please login to the form below

Not currently logged in

Bristol Myers Squibb releases positive trial results for plaque psoriasis treatment

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities


Bristol Myers Squibb has revealed two-year results from the POETYK PSO trial involving its psoriasis therapy, deucravacitinib.

The study demonstrated durable efficacy and a consistent safety profile among adult patients with moderate to severe plaque psoriasis, and clinical efficacy was maintained throughout two years of the treatment.

Plaque psoriasis is a chronic, systemic immune-mediated disease associated with multiple serious comorbidities and there remains a strong unmet need for new treatments, particularly oral medicines.

At least 100 million people worldwide have some form of psoriasis, including around 14 million people in Europe and approximately 7.5 million in the US.

Overall observed safety of deucravacitinib effectively spanned 2,482 patient years of treatment and was consistent with previously presented pivotal phase 3 trials.

Adverse events continued to be predominantly mild or moderate, with the most frequent being nasopharyngitis, upper respiratory tract infections or headaches.

Professor Richard Warren, consultant dermatologist at Salford Royal Hospital, said: “Long-term research showing durable efficacy, in addition to a well-understood safety profile, is critical for clinicians and patients making treatment decisions, and the new two-year data underscores the potential of deucravacitinib to be an important new oral treatment option for people living with moderate to severe plaque psoriasis who require systemic therapy.”

No emerging safety signals were observed and serious adverse events causing patients to drop out of the two-year trial remained low.

Deucravacitinib treatment did not increase the risk or severity of COVID-19 infection, while overall rates of COVID-19-related hospitalisation or death during the trial were consistent with epidemiologic rates.

Jonathan Sadeh, senior vice president of immunology and fibrosis development at Bristol Myers Squibb, said: “Our pioneering research is leading to the potential for novel, well-tolerated treatment options for individuals impacted by serious immune-mediated diseases like psoriasis.

“The long-term follow-up results add to the growing body of evidence for deucravacitinib, reinforcing its potential to offer patients with moderate to severe plaque psoriasis an oral treatment option that addresses current gaps in care,” he added.

Article by
John Pinching

13th May 2022

From: Research, Healthcare



COVID-19 Updates and Daily News

Featured jobs


Add my company

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...